Schering

EQS-News: iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer

Retrieved on: 
Tuesday, September 5, 2023
Apollon, Myelocyte, Duke University, Business development, Therapy, Neoplasm, Cancer, Doctor of Philosophy, Schering AG, Humboldt University of Berlin, Boehringer Ingelheim, Patent, CBO, Growth, Schering, BD, Fine chemical, Bayer

Martinsried / Munich, Germany, September 5, 2023 - iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth.

Key Points: 
  • Martinsried / Munich, Germany, September 5, 2023 - iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth.
  • Dr. Debus is an accomplished life science leader with 27 years of industry experience and an outstanding track record in Business Development & Licensing.
  • Dr. Apollon Papadimitriou, CEO of iOmx, said: “Nils brings us significant strategic business expertise with a proven success in building partnerships and executing transformative collaborations and acquisitions.
  • Dr. Debus is a microbiologist by training and holds a PhD in embryonic stem cell research from Humboldt University (Berlin, Germany).

Bayer Announces Senior Bayer Representative and President of Bayer U.S.

Retrieved on: 
Wednesday, June 21, 2023
Health, Science, Fitness & Nutrition, Pharmaceutical, Research, BIO, Senior, GROW, Lead, Pharmaceutical Research and Manufacturers of America, Pharmacy, Multimedia, Schering AG, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Medication, Organization, Acquisition, Patient, Child, CFO, Growth, Commercial Operating System, Schering, FDA, Pharmaceutical industry, Management, Bayer

Bayer, one of the country’s leading life-sciences companies, today announced its new Senior Bayer Representative and President of Bayer U.S.

Key Points: 
  • Bayer, one of the country’s leading life-sciences companies, today announced its new Senior Bayer Representative and President of Bayer U.S.
  • “I am honored to lead Bayer U.S.,” said Sebastian Guth, incoming Senior Bayer Representative and President of Bayer U.S. and Pharmaceuticals North America.
  • Previously, Guth served as President & Chief Executive Officer of Bayer Yakuhin Ltd., Osaka, leading Bayer's healthcare business in Japan.
  • Following Bayer's acquisition of Schering in 2006, Sebastian served as Chief Executive Officer of Bayer Turk, Istanbul, and was Senior Representative of the Bayer Group in Turkey.

Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer

Retrieved on: 
Monday, October 10, 2022
Merck, Therapy, VP, Food and Drug Administration Amendments Act of 2007, Cornell University, University, Kyowa Hakko Kirin, Peripheral nervous system, CEO, Geriatrics, Translation, Psychiatry, Wharton School of the University of Pennsylvania, Karolinska Institute, Athena, Drug development, Wilmar International, Lists of diseases, Investment, Internal medicine, Company, IP, GLOBE, CMO, Critical Path Institute, Schering, University of Pennsylvania, AstraZeneca, Risk, PD, Growth, Business administration, Research, Icahn School of Medicine at Mount Sinai, Neurology, CNS, AD, Neurodegeneration, Coalition, Central nervous system, Migraine, Genomics, Patient, Kyōwa, Partnership, North American Medical Management, Food, MD, Forward-looking statement, Insomnia, Mount Sinai, Pharmaceutical industry, Medicine, Pfizer, Sanofi

Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical Officer

Key Points: 
  • Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical Officer
    Dr. Cantillon brings over 25 years experience in senior Central Nervous System (CNS) development roles at Merck, Pfizer, Kyowa and Reviva Pharmaceuticals
    SINGAPORE and DENVER, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the appointment of Marc Cantillon, MD, as Chief Medical Officer (CMO) of the Company.
  • Prior to this, Dr. Cantillon was Chief Medical Officer of Green Valley Pharmaceuticals, a biopharmaceutical company developing carbohydrate drugs in Parkinsonss Disease (PD) and Alzheimers Disease (AD).
  • Commenting on the appointment, Charles Stacey, CEO of Cerecin, said, We are very pleased to welcome Marc to our executive team.
  • Dr. Marc Cantillon, CMO of Cerecin, said, Cerecins metabolic approach to neurodegenerative disease has the potential to deliver novel treatment options to patients across several disease areas.

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

Phosplatin Therapeutics Appoints Sebastian Guth, PhD, to Board of Directors

Retrieved on: 
Tuesday, January 4, 2022
Growth, NCI, Children's Aid Society, CRADA, Schering AG, Pharmacy, Board, Cancer, Trial of the century, Toxicity, Doctor of Philosophy, Family, Merck Serono, Drug resistance, Medication, Company, Therapy, Immunogenic cell death, Mid-America Regional Council, Research, Board of directors, Schering, Biotechnology Innovation Organization, Merck Group, Acquisition, Pharmaceutical industry, Bayer

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Phosplatin Therapeutics Inc. , a clinical stage pharmaceutical company focused on oncology therapeutics, todayannounced the appointment of Sebastian Guth, PhD, to the company's Board of Directors.

Key Points: 
  • NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Phosplatin Therapeutics Inc. , a clinical stage pharmaceutical company focused on oncology therapeutics, todayannounced the appointment of Sebastian Guth, PhD, to the company's Board of Directors.
  • Dr. Guth brings a wealth of international biopharmaceutical leadership experience to Phosplatin, including his current position as President of Bayer Pharmaceuticals Americas.
  • Phosplatin will draw upon his guidance as the Company continues to evolve and advance its lead therapeutic candidate, PT-112.
  • In addition to serving on the Phosplatin Board of Directors, Dr. Guth also serves on the Board of the Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization, and Children's Aid.

Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

Retrieved on: 
Monday, August 23, 2021
PD, Company, UnitedHealth Group, Richard Barker (life sciences and healthcare leader), Pramipexole, Group, Therapy, Brooklyn Law School, Parkinson, Acquisition, Union College, GLOBE, International, Schering-Plough, Walgreens Boots Alliance, Board of directors, Parkinson's disease, Merck & Co., Merck, Esperies, Commerce, Marketing, Alliance, Alliance Boots, Development, Gesellschaft mit beschränkter Haftung, List of life sciences, Board, Safety, Risk, Esperion Therapeutics, Patient, CEO, FDA, Pharmacy, Schering, Pharma, Technology, Pharmaceutical industry, Management

I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.

Key Points: 
  • I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • Mr. Berkowitz commented, "I am impressed by Pharma Two Bs progress to date and honored to be appointed as Chairman.
  • I look forward to working closely with Sheila and the rest of the Board and contributing to the company's future success."
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.

Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

Retrieved on: 
Thursday, August 12, 2021
Alliance Boots, Walgreens Boots Alliance, Gesellschaft mit beschränkter Haftung, Merck & Co., Board of directors, UnitedHealth Group, Schering-Plough, Pramipexole, GLOBE, List of life sciences, Pharma, FDA, Alliance, Therapy, Safety, CEO, Esperion Therapeutics, Marketing, Parkinson's disease, Schering, Acquisition, Union College, Development, Parkinson, Technology, Company, Esperies, Risk, Merck, International, Brooklyn Law School, PD, Commerce, Board, Group, Pharmacy, Richard Barker (life sciences and healthcare leader), Patient, Pharmaceutical industry, Management

REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.

Key Points: 
  • REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.
  • I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • Mr. Berkowitz commented, "I am impressed by Pharma Two Bs progress to date and honored to be appointed as Chairman.
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.

Blue Water Vaccines Announces the Appointment of Ronald R. Cobb as the Head of Science and Discovery

Retrieved on: 
Wednesday, August 11, 2021
Hospital, OH, Cincinnati Children's Hospital Medical Center, Wake Forest University, AOM, CEO, Patient, St. Jude Children's Research Hospital, Media, Contract, Ology Bioservices, Medical College of Georgia, Immune system, Tobacco Products Scientific Advisory Committee, Norovirus, Vaccine, University, Solution, Inflammation, CCHMC, Streptococcus pneumoniae, Research, Schering-Plough, Epitope, Schering, Discovery, VLP, Infection, Medical college, Drug development, Pharmaceutical industry

CINCINNATI, August 11, 2021 /PRNewswire/ --Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery.

Key Points: 
  • CINCINNATI, August 11, 2021 /PRNewswire/ --Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery.
  • "We look forward to him leading Blue Water Vaccines' pipeline initiatives, which focus on treating and preventing pathogen infections."
  • "I am excited to join the growing team at Blue Water Vaccines and to be involved in the critical process of bringing life-saving vaccines to patients globally," noted Dr. Cobb.
  • As the head of Blue Water Vaccines' scientific initiatives, I plan to propel these ongoing programs forward and establish their clinical path."

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

Retrieved on: 
Friday, July 30, 2021
Pharmaceutical companies, Lexicon Pharmaceuticals, Schering-Plough, Schering, Companies, Pharmaceutical industry

THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021.

Key Points: 
  • THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021.
  • Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having previously built global medical organizations at three separate companies.
  • Prior to the merger, he held a variety of medical and commercial management positions with Schering-Plough, including group vice president, head of global medical affairs.
  • We are very pleased to have Dr. Granowitz join Lexicon as our chief medical officer, said Lonnel Coats, Lexicons president and chief executive officer.